首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7171篇
  免费   443篇
  国内免费   48篇
耳鼻咽喉   87篇
儿科学   228篇
妇产科学   57篇
基础医学   846篇
口腔科学   162篇
临床医学   477篇
内科学   1811篇
皮肤病学   169篇
神经病学   509篇
特种医学   286篇
外科学   1276篇
综合类   46篇
一般理论   1篇
预防医学   171篇
眼科学   193篇
药学   513篇
中国医学   22篇
肿瘤学   808篇
  2023年   65篇
  2022年   48篇
  2021年   236篇
  2020年   135篇
  2019年   184篇
  2018年   253篇
  2017年   179篇
  2016年   194篇
  2015年   190篇
  2014年   255篇
  2013年   332篇
  2012年   468篇
  2011年   477篇
  2010年   241篇
  2009年   209篇
  2008年   384篇
  2007年   373篇
  2006年   346篇
  2005年   384篇
  2004年   374篇
  2003年   308篇
  2002年   289篇
  2001年   168篇
  2000年   162篇
  1999年   175篇
  1998年   78篇
  1997年   61篇
  1996年   64篇
  1995年   38篇
  1994年   43篇
  1993年   43篇
  1992年   112篇
  1991年   89篇
  1990年   87篇
  1989年   91篇
  1988年   54篇
  1987年   45篇
  1986年   50篇
  1985年   42篇
  1984年   25篇
  1983年   32篇
  1982年   19篇
  1979年   29篇
  1978年   24篇
  1977年   20篇
  1975年   19篇
  1974年   18篇
  1973年   18篇
  1970年   18篇
  1969年   19篇
排序方式: 共有7662条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的分析中性粒细胞与淋巴细胞比值(NLR)对急性腔隙性脑梗死患者病情进展的预测价值。方法根据病情进展与否将2012年2月~2017年1月收治的230例急性腔隙性脑梗死患者分为进展组(40例)与非进展组(190例),记录各组中性粒细胞绝对值、淋巴细胞绝对值等指标,计算NLR。受试者工作特征(ROC)曲线分析NLR等对急性腔隙性脑梗死患者病情进展预测的特异度、敏感度,Pearson相关性分析NLR等指标与mRS评分的关系。结果进展组NLR、白细胞计数、中性粒细胞绝对值均显著高于非进展组(P 0. 05);淋巴细胞绝对值显著低于非进展组(P 0. 05)。NLR对进展性腔隙性脑梗死(PLI)预测曲线下面积(AUC)为0. 800,最佳临界值3. 25,敏感度85. 06%,特异度70. 68%;白细胞计数、中性粒细胞绝对值、淋巴细胞绝对值对PLI预测AUC分别为0. 650、0. 745、0. 615。进展组预后良好率显著低于非进展组(P 0. 05)。NLR、中性粒细胞绝对值、白细胞计数与mRS评分正相关(P 0. 05)。结论 NLR值对急性腔隙性脑梗死患者病情进展有一定的预测价值,有可能作为患者预后评估的有效指标。  相似文献   
4.
Cancer‐derived myocardial damage is an important cause of death in cancer patients. However, the development of dietary interventions for treating such damage has not been advanced. Here, we investigated the effect of dietary intervention with lauric acid (LAA) and glucose, which was effective against skeletal muscle sarcopenia in a mouse cachexia model, on myocardial damage. Treatment of H9c2 rat cardiomyoblasts with lauric acid promoted mitochondrial respiration and increased ATP production by Seahorse flux analysis, but did not increase oxidative stress. Glycolysis was also promoted by LAA. In contrast, mitochondrial respiration and ATP production were suppressed, and oxidative stress was increased in an in vitro cachexia model in which cardiomyoblasts were treated with mouse cachexia ascites. Ascites‐treated H9c2 cells with concurrent treatment with LAA and high glucose showed that mitochondrial respiration and glycolysis were promoted more than that of the control, and ATP was restored to the level of the control. Oxidative stress was also reduced by the combined treatment. In the mouse cachexia model, myocardiac atrophy and decreased levels of a marker of muscle maturity, SDS‐soluble MYL1, were observed. When LAA in CE‐2 diet was orally administered alone, no significant rescue was observed in the cancer‐derived myocardial disorder. In contrast, combined oral administration of LAA and glucose recovered myocardial atrophy and MYL1 to levels observed in the control without increase in the cancer weight. Therefore, it is suggested that dietary intervention using a combination of LAA and glucose for cancer cachexia might improve cancer‐derived myocardial damage.  相似文献   
5.
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resistance of various cancers to molecular‐targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib‐resistant cell lines from HER2‐amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib‐resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1‐amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2‐targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome.  相似文献   
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号